产品详细信息
- 在 2 - 3 周内改善细胞成熟状态
- 能够精确控制不同时间段的搏动频率
- 改善心肌细胞对正性肌力化合物和肌小节结构的反应。
- 可扩展的系统，您可以对几个孔中的细胞和多达 6 块 48 孔或 96 孔 E-Plate 中的细胞进行刺激。
- 与钙离子检测、高内涵显微镜、电压敏感染料和酶标仪等兼容。
- 应用简报
-
Multimodal Connected Workflow for Cardiotoxicity Assessment Using Human iPSC-Derived Cardiomyocytes
This application note demonstrates the feasibility and use of combining multiple cell-based in vitro assays from Agilent that use diverse analytical technologies to investigate the cardiac liability of drugs.
- 应用简报
- English
- 2022 年 9 月 26 日
- 1002.14 KB
Connected Workflow: Assessment of Inotropic Compounds in PacedCardiomyocytes Using Calcium Imaging
This app note demonstrates the feasibility of using a connected workflow to evaluate the effect of inotropic compounds on electrically paced human iPSC derived cardiomyocytes (hiPSC-CMs) through calcium imaging
- 应用简报
- English
- 2022 年 6 月 6 日
- 2.93 MB
Cardiotoxicity Assessment of Antiviral Drugs Using the Agilent xCELLigence RTCA CardioECR System
This study used the Agilent xCELLigence RTCA CardioECR system with human iPSC-derived cardiomyocytes (hiPSC-CMs) to evaluate cardiac safety/toxicity of antiviral drugs.
- 应用简报
- English
- 2021 年 11 月 17 日
- 1.58 MB
Assessment of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Disease Models Using the Agilent xCELLigence CardioECR System
A demonstration of the use of the Agilent xCELLigence RTCA CardioECR system to compare functional profiles of contractility and electrophysiology between an PS-iPSC-CM disease model and its isogenic control.
- 应用简报
- English
- 2021 年 9 月 10 日
- 2.82 MB
Using the Agilent xCELLigence RTCA ePacer for Functional Maturation of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
This application note presents a method for improving human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) maturation using the Agilent xCELLigence RTCA ePacer system.
- 应用简报
- English
- 2021 年 2 月 11 日
- 5.39 MB
A Real-Time Impedance Analysis Instrument for Cardiac Safety and Toxicity Assessment
In this application note, the RTCA Cardio instrument is used with human stem cell-derived cardiomyocytes (iCell Cardiomyocytes) for assessment of the cardiac safety profile of leading compounds or drug candidates during drug development.
- 应用简报
- English
- 2020 年 12 月 4 日
- 2.01 MB
The Agilent xCELLigence RTCA CardioECR System: A Multiparametric Functional Analysis Instrument for Cardiac Safety and Toxicity Assessment
In this application note, we used the xCELLigence RTCA CardioECR system (CardioECR system) in conjunction with hiPS-CMs for the assessment of preclinical cardiac risks.
- 应用简报
- English
- 2020 年 7 月 16 日
- 4.82 MB
- 产品样本